After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
EXEL belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Exelixis Inc is $6.28B. A total of 1.8 million shares were traded on the day, compared to an average of 2.14M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, EXEL has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 30 BUYs and 35 SELLs from insiders. Insiders purchased 2,381,590 shares during that period but sold 1,228,385.
In the most recent transaction, JOHNSON DAVID EDWARD bought 190,000 shares of EXEL for 20.70 per share on Feb 21. After the transaction, the Director now owns 1,100,730 company shares. In a previous transaction on Dec 14, Haley Patrick J. sold 50,000 shares at 23.35 per share. EXEL shares that EVP, Commercial owns now total 307,687.
Among the insiders who sold shares, Hessekiel Jeffrey disposed of 25,000 shares on Dec 13 at a per-share price of $23.01. This resulted in the EVP, General Counsel & Sec holding 533,345 shares of EXEL after the transaction. In another insider transaction, Haley Patrick J. sold 14,149 shares at $22.50 per share on Dec 12. Company shares held by the EVP, Commercial now total 307,687.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for EXEL in the last 3 months, the mean price target is $26.74 with high estimates of $32.00 and low estimates of $18.00. In terms of 52-week highs and lows, EXEL has a high of $24.34 and a low of $16.15.
As of this writing, EXEL has an earnings estimate of $0.23 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of $0.47 per share and a lower estimate of $0.11. The company reported an EPS of $0 in the last quarter, which was -100.00% lower than expectations of $0.09.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. EXEL’s latest balance sheet shows that the firm has $1.47B in Cash & Short Term Investments as of fiscal 2021. There were $51.27M in debt and $337.59M in liabilities at the time. Its Book Value Per Share was $7.48, while its Total Shareholder’s Equity was $2.21B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EXEL is Buy with a score of 4.63.
